Defining the Role of CD4+CD25+ Immunoregulatory T-Cells in the Treatment of Patients With Advanced Ovarian Cancer Who Receive Dendritic Cell Based Vaccine Therapies.
Phase of Trial: Phase II
Latest Information Update: 20 Dec 2017
At a glance
- Drugs Denileukin diftitox (Primary) ; Ovarian cancer vaccine
- Indications Ovarian cancer
- Focus Pharmacodynamics
- 14 Dec 2017 Planned End Date changed from 1 Jul 2015 to 1 Jul 2018.
- 14 Dec 2017 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2018.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.